Glycostem Therapeutics
Glycostem is a clinical stage biotech company developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells.
Glycostem Therapeutics is a business in biotechnology, life science, pharmaceutical based in European Union (EU), Europe, Middle East, and Africa (EMEA), founded in 2007.
Within the biotechnology, life science, pharmaceutical space, the company focuses on its core offering rather than a broad product line.
The business is associated with European Union (EU), Europe, Middle East, and Africa (EMEA).
The company is listed at the Private company stage of development.
The company reports a headcount in the c_00011_00050 range.
| Sector | Biotechnology, Life Science, Pharmaceutical |
|---|---|
| Headquarters | European Union (EU), Europe, Middle East, and Africa (EMEA) |
| Founded | 2007 |
| Employees | c_00011_00050 |
| Stage | Private company |
Website: glycostem.com
Emails and contact routes are reserved for registered members.
Create a free account
Create a free account